Table 2:
Patient characteristics
| Trial | Intervention | Patients (n) analyzed | Age (years) | Sex (female) | STS score | PAD | CVD |
|---|---|---|---|---|---|---|---|
| PARTNER 1A [16] | TAVR | 348 | 84 (7) | 147 (42%) | 11.8 (3.3) | 149 (43%) | 96 (29%) |
| SAVR | 351 | 85 (6) | 153 (43%) | 11.7 (3.5) | 142 (42%) | 87 (27%) | |
| PARTNER 2A [19] | TAVR | 1011 | 82 (7) | 463 (46%) | 5.8 (2.1) | 282 (28%) | 325 (32%) |
| SAVR | 1021 | 82 (7) | 461 (45%) | 5.8 (1.9) | 336 (33%) | 317 (31%) | |
| PARTNER 3 [45] | TAVR | 496 | 73 (6) | 32% | 1.9 (0.7) | 6.9% | 3.4% |
| SAVR | 454 | 74 (6) | 29% | 1.9 (0.6) | 7.3% | 5.1% | |
| CoreValve US [17] | TAVR | 391 | 83 (7) | 184 (47%) | 7.3 (3.0) | 159 (41%) | 97 (25%) |
| SAVR | 359 | 83 (6) | 171 (48%) | 7.5 (3.3) | 150 (42%) | 90 (25%) | |
| SURTAVI [18] | TAVR | 864 | 80 (6) | 366 (42%) | 4.4 (1.5) | 266 (31%) | 151 (18%) |
| SAVR | 796 | 80 (6) | 358 (45%) | 4.5 (1.6) | 238 (30%) | 130 (16%) | |
| EVOLUT-LR [46] | TAVR | 730 | 74 (6) | 266 (36.4%) | 2.0 (0.2) | 54 (8%) | 74 (10%) |
| SAVR | 684 | 74 (6) | 233 (34.1%) | 2.0 (0.2) | 56 (8%) | 82 (12%) | |
| NOTION [30] | TAVR | 145 | 79 (5) | 67 (46%) | 2.9 (1.6) | 6 (4%) | 24 (17%) |
| SAVR | 135 | 79 (5) | 64 (47%) | 3.1 (1.7) | 9 (7%) | 22 (16%) | |
| UK-TAVI [31] | TAVR | 458 | NRa | 211 (46%) | 2.6 [2.0–3.5] | 40 (9%) | 75 (16%) |
| SAVR | 455 | NRa | 213 (47%) | 2.7 [2.0–3.5] | 35 (8%) | 67 (15%) |
Continuous data are reported as mean and (standard deviation), except in UK-TAVI, where STS score is reported by median and [25th–75th percentile].
a
Study reported categorized age groups.
AT: as-treated, CVD: cerebrovascular disease, ITT: intention to treat, mITT: modified ITT; PAD: peripheral arterial disease, SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons, TAVR: transcatheter aortic valve replacement.